betrixaban

An orally active inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Betrixaban is primarily excreted unchanged in… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2018
051020082018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
BACKGROUND Stroke is a morbid and potentially mortal complication among patients hospitalized with acute medical illness. The… (More)
  • table I
  • table 5
Is this relevant?
2017
2017
BACKGROUND The APEX trial assessed the safety and efficacy of extended-duration thromboprophylaxis using betrixaban versus… (More)
  • table I
  • table II
  • table III
  • table IV
  • figure I
Is this relevant?
2016
2016
BACKGROUND Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration… (More)
  • table 1
  • table 3
Is this relevant?
2014
2014
The recently introduced oral anticoagulants, dabigatran, rivaroxaban and apixaban, were shown, in randomized controlled trials… (More)
Is this relevant?
2014
2014
Randomized clinical trials have identified a population of acute medically ill patients who remain at risk for venous… (More)
Is this relevant?
2013
2013
AIMS Patients with atrial fibrillation (AF) are at increased risk of stroke. Betrixaban is a novel oral factor Xa inhibitor… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2013
2013
OBJECTIVE To evaluate the effects of the anticoagulant betrixaban on individual heart rate-corrected QT (QTcI). RESEARCH DESIGN… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2011
2011
 
Is this relevant?
2009
2009
Betrixaban is an oral direct inhibitor of factor Xa (FXa) being developed for the prevention of venous thromboembolism (VTE). Its… (More)
Is this relevant?
2009
2009
Systematic SAR studies of in vitro factor Xa inhibitory activity around compound 1 were performed by modifying each of the three… (More)
Is this relevant?